Skip to main content

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

Citations of this article
Mendeley users who have this article in their library.


Safe, effective adjuvants that enhance vaccine potency, including induction of neutralizing Abs against a broad range of variant strains, is an important strategy for the development of seasonal influenza vaccines which can provide optimal protection, even during seasons when available vaccines are not well matched to circulating viruses. We investigated the safety and ability of Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE), a synthetic Toll-like receptor (TLR)4 agonist formulation, to adjuvant FluzoneH in mice and non-human primates. The GLA-SE adjuvanted Fluzone vaccine caused no adverse reactions, increased the induction of T helper type 1 (TH1)-biased cytokines such as IFNγ, TNF and IL-2, and broadened serological responses against drifted A/H1N1 and A/H3N2 influenza variants. These results suggest that synthetic TLR4 adjuvants can enhance the magnitude and quality of protective immunity induced by influenza vaccines. © 2010 Coler et al.




Coler, R. N., Baldwin, S. L., Shaverdian, N., Bertholet, S., Reed, S. J., Raman, V. S., … Reed, S. G. (2010). A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS ONE, 5(10).

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free